A5060143479- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- Bladder and Urothelial Cancer Treatments
- Liver Disease Diagnosis and Treatment
- Blood Coagulation and Thrombosis Mechanisms
- Signaling Pathways in Disease
- Urologic and reproductive health conditions
- Thyroid Cancer Diagnosis and Treatment
- Lipid metabolism and disorders
- Hepatitis C virus research
- Viral gastroenteritis research and epidemiology
- Angiogenesis and VEGF in Cancer
- Urinary and Genital Oncology Studies
- Bone health and treatments
- Cell Adhesion Molecules Research
- Animal Virus Infections Studies
- Autopsy Techniques and Outcomes
- Marine Biology and Environmental Chemistry
- Axon Guidance and Neuronal Signaling
- Cutaneous Melanoma Detection and Management
- Hepatocellular Carcinoma Treatment and Prognosis
- CAR-T cell therapy research
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
2016
University of Rome Tor Vergata
2016
Candiolo Cancer Institute
2014
COVID-19 is a highly infectious disease caused by newly emerged coronavirus (SARS-CoV-2) that has rapidly progressed into pandemic. This unprecedent emergency stressed the significance of developing effective therapeutics to fight current and future outbreaks. The receptor-binding domain (RBD) SARS-CoV-2 surface Spike protein main target for vaccines represents helpful "tool" produce neutralizing antibodies or diagnostic kits. In this work, we provide detailed characterization native RBD...
Abstract COVID-19 is a highly infectious disease caused by newly emerged coronavirus (SARS-CoV-2) that has rapidly progressed into pandemic. This unprecedent emergency stressed the significance of developing effective therapeutics to fight current and future outbreaks. The receptor-binding domain (RBD) SARS-CoV-2 surface Spike protein main target for vaccines represents helpful “tool” produce neutralizing antibodies or diagnostic kits. In this work, we provide detailed characterization...
Abstract The COVID-19 pandemic caused by the β-coronavirus SARS-CoV-2 has made development of safe and effective vaccines a critical global priority. To date, four have already been approved European American authorities for preventing but additional vaccine platforms with improved supply logistics profiles remains pressing need. Here we report preclinical evaluation novel candidate based on electroporation engineered, synthetic cDNA encoding viral antigen in skeletal muscle, technology...
VOLUME 289 (2014) PAGES 19466–19476 The affiliation of the corresponding author, Prof. Marco Arese, as well address, should read follows: Dept. Oncology, University Torino Medical School and Laboratory Neurovascular Biology, Candiolo Cancer Institute, FPO-IRCCS Str. Prov. 142, km 3.95, 10060 Candiolo, Torino, Italy. Tel.: 390119933508; Fax: 390119933524; E-mail: [email protected].